SCOTUS’ denial of certiorari in Idenix v Gilead poses especially difficult IP questions for universities and small biotechs
Recent caselaw has raised serious doubts over the enforceability of US genus claims, leaving life sciences innovators in a quandary
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.